http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021534727-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-531 |
| filingDate | 2019-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2021534727-A |
| titleOfInvention | Nanoantibodies capable of binding to SFTSV and their use |
| abstract | The present invention comprises three complementarity determining regions CDRs 1-3, where the CDR1 sequence is or comprises one of the sequences shown in SEQ ID NOs: 1-74 and the CDR2 sequences are SEQ ID NOs: 75-. With respect to a polypeptide capable of binding to SFTSV, which is one of or comprises one of the sequences shown in 151 and whose CDR3 sequence is one of or comprises one of the sequences shown in SEQ ID NO: 152-232. The present invention develops nanoantibody drugs and researches and develops diagnostic kits against SFTS, which has a high lethality but lacks effective vaccines and specific antiviral drugs, produces GN proteins, and immunizes Futacobracta. Then, by using a platform technology for displaying Nanobodies using a phage library, etc., the nanoantibody VHH specifically bound to GN is screened, its CDR sequence is identified, a humanized antibody SNB is constructed, and humanized mice are constructed. The model assesses the therapeutic effect of SNB in the treatment of SFTSV infections in vivo. The present invention provides a potential new drug for nanoantibodies for the clinical treatment of SFTS, as well as a detection kit for the diagnosis of SFTS. [Selection diagram] Fig. 2 |
| priorityDate | 2019-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.